AD Related Dementias Focus

Epidemiology/Population Studies

Health Equity: Identify risk factors across diverse populations (Milestone 1.I)
Assess epidemiology and mechanistic pathways of disparities in health burden of AD/ADRD.
Health Equity: Monitor trends of different ADRDs in diverse populations (Milestone 1.J)
Develop a system to monitor the magnitude and trends in health disparities in incidence of AD/ADRD.
LBD: Characterize LBD brain pathology (Milestone 1.K)
Characterize nervous system changes in LBD cohorts that have come to autopsy to identify disease-specific underlying mechanisms to guide biomarker and therapeutic approaches.
LBD: Understand LBD genetic, epigenetic, and environmental influences (Milestone 1.L)
Identify novel common and rare genetic variants, epigenetic changes, and environmental influences that impact the risk for and clinical features of LBD.
FTD Studies: Understand the natural history of FTD (Milestone 1.M)
Understand phenotypic heterogeneity and natural history in FTD.
TBI in AD/ADRD: Encourage research collaborations (Milestone 1.N)
Encourage crosstalk and interdisciplinary collaboration between TBI and dementia researchers.
TBI in AD/ADRD: Develop infrastructure for risk factor identification (Milestone 1.O)
Establish infrastructure to study TBI as a risk factor for AD/ADRD.
Health Equity: Understand and reduce barriers to health equity (Milestone 1.S)
Assess the social, economic and structural impediments to equity in AD/ADRD assessment, diagnosis, and referrals, and impacts on health and economic outcomes.  
FTD: Studying FTD causes and risk factors in people (Milestone 1.T)
Understand FTD epidemiology and genetics in diverse populations, including how socioeconomic and ethnocultural status affects disease risk and manifestations.  
MED COVID-19: Understanding barriers to health equity (Milestone 1.U)
Impact of COVID-19 on AD/ADRD: Understanding barriers to health equity

Disease Mechanisms

Diagnosis, Assessment, and Disease Monitoring

Translational and Clinical Research Interventions – Non-Pharmacological

VCID Clinical Trials: Interventions to reduce vascular risk factors (Milestone 8.E)
Test for efficacy across the spectrum of VCID severity

Translational and Clinical Research Interventions – Pharmacological

Translational Research and Clinical Interventions – Trial Innovation

Dementia Care and Impact of Disease

Research Resources